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Introduction {#sec005}
============

As illustrated with the most recent data \[[@pone.0194976.ref001]\], the incidence of extracorporeal membrane oxygenation (ECMO) support has increased for over a decade. In-hospital mortality of patients assisted with veno-arterial (VA-ECMO) or veno-venous (VV-ECMO) ECMO remains high, secondary to the severity of illness leading to ECMO support, but also to frequent and severe complications, most being infectious \[[@pone.0194976.ref002]\]. Hence, nosocomial infections under ECMO support (from 14.8 to 75.5 infectious episodes per 1000 ECMO days) are associated with longer duration of ECMO support, mechanical ventilation, and ICU and hospital lengths of stay \[[@pone.0194976.ref003]--[@pone.0194976.ref006]\].

Although pneumonia appears to be the most frequent infection under ECMO, no specific data exist on this specific issue. Epidemiology, risk factors, microbiology, specific outcome or risks of treatment failure (TF) of ventilator-associated pneumonia under ECMO support remain unknown. However, severity of patients assisted with ECMO, immunosuppression secondary to extracorporeal circulation \[[@pone.0194976.ref007]--[@pone.0194976.ref009]\] as well as changes in antibiotics pharmacokinetics under ECMO \[[@pone.0194976.ref010]--[@pone.0194976.ref012]\] make us think that VAP under ECMO is a distinct entity.

To address this issue, we aimed to investigate the epidemiology, risk factors, microbiology and outcomes of VAP, and to identify risk factors of TF in a large and well-defined cohort of ICU patients treated with VA-ECMO.

Methods {#sec006}
=======

Design and setting {#sec007}
------------------

This observational, retrospective and monocentric study was conducted in the Surgical Intensive Care Unit of Cardiology Institute in La Pitié-Salpêtrière University Hospital (Paris, France). We included all patients assisted with VA-ECMO and admitted in our unit.

Standard care procedure for patients on ECMO {#sec008}
--------------------------------------------

Procedures for implantation, daily management and weaning were realized according to the recommendations of the Extracorporeal Life Support Organization (ELSO) and are described in [S1 File](#pone.0194976.s005){ref-type="supplementary-material"}. For patients with peripheral cannulation, prophylactic antibiotic therapy was performed with second-generation cephalosporin as a single intravenous injection (cefazoline 2g) at the time of ECMO implantation. Patients with central cannulation received prophylactic antibiotic for the surgery (cefazoline 2 g within the hour prior to incision, then 1g every 4h), but no antibiotic prophylaxis was continued during the course of ECMO.

Prevention of VAP {#sec009}
-----------------

VAP prevention is based on a combination of measures: orotracheal intubation, endotracheal tube cuff pressure maintained between 20 and 30 cm H~2~O, oral chlorhexidine application four times per day, semi recumbent body positioning (30 to 45°) when possible. Sedation is patient-targeted, relying on assessments eight times per day of Richmond Agitation-Sedation Scale (RASS). Patients are started on enteral tube feeds within 48 h of intubation whenever possible.

Definitions {#sec010}
-----------

VAP diagnosis included a clinical suspicion (≥ two criteria including fever \> 38.5 ° C, leukocytosis \> 10^9^/L or leukopenia \< 4.10^8^/L, purulent tracheobronchial secretions and a new or persistent infiltrate on chest radiography), and confirmation by a positive quantitative culture of a respiratory sample: bronchoalveolar lavage fluid (significant threshold ≥10^4^ colony-forming units (CFU).mL^-1^) or plugged telescopic catheter (significant threshold ≥10^3^ CFU.mL^-1^) or quantitative endotracheal aspirate distal pulmonary secretion samples (significant threshold ≥10^6^ CFU.mL^-1^).

Ventilator-associated pneumonia under ECMO support was defined *post hoc* by 2 independent infectious experts (AB, CB) as a VAP occurring in patients assisted with VA-ECMO for more than 24 hours or withdrawn for less than 48 hours. Immunosuppression was defined as HIV, immunosuppressive therapy, or corticosteroids\> 0.5 mg/kg per day for more than a month. In case of persistence, worsening or recurrence of clinical criteria, a new respiratory sample was performed. After 6 days of antibiotic therapy against the identified pathogen, and up to 48 hours after the end of antibiotic therapy, we considered a positive quantitative culture of the same pathogen as a persistence of VAP ([S1 Fig](#pone.0194976.s003){ref-type="supplementary-material"}). If this new respiratory sample was performed after ≥ 48 hours without antibiotic treatment, we considered positive quantitative culture of the same pathogen as a relapse of VAP. During antibiotic therapy of initial VAP, and up to 48 hours after the end of antibiotic therapy, we considered a positive quantitative culture of the new pathogen as a superinfection. After ≥ 48 hours without antibiotic treatment, we considered positive quantitative culture of the new pathogen as a new VAP. Nevertheless, because the occurrence of a new VAP, documented with a new pathogen is part of the prolonged ventilation of a severe ICU patient, and does not appear to be directly related to the presence of ECMO, we did not consider it as a treatment failure. Attributable death to VAP was defined as death under ECMO during antibiotic therapy for VAP without any other evident cause of death, or death under ECMO secondary to septic shock of pulmonary origin.

Our primary endpoint was treatment failure, a composite of attributable death to pneumonia or persistence or relapse of pneumonia within 28 days of the first episode.

Data collection {#sec011}
---------------

The following information were recorded retrospectively for each patient: demographic data; clinical variables; comorbidities; reason for ECMO; duration of ECMO support, mechanical ventilation, ICU stay, and hospital stay; presence and type of infectious complications, hemorrhagic complications, digestive complications, neurologic complications and acute kidney injury.

Ethics approval and consent to participate {#sec012}
------------------------------------------

The ethics committee Ile de France 5 approved the collection of data compiled in our ECMO registry (Reference B-7-15). Due to the retrospective design of the study, and in accordance with the decision of the ethics committee, no consent was needed.

Statistical analysis {#sec013}
--------------------

Results are expressed as number of patients (%), or mean (± Standard deviation). When indicated, 95% CIs were calculated. Influence of the occurrence of VAP on overall survival, ECMO assistance duration and mechanical ventilation duration were assessed with univariate Cox regression models, with ECMO-associated pneumonia as a time-dependant covariable. Kaplan-Meier representation of the overall survival according to ECMO-associate pneumonia occurrence was obtained using the Simon and Makuch method \[[@pone.0194976.ref013]\].

Univariate and multivariate Poisson regression survival models with the log of ECMO duration as an offset term were used to evaluate risk factors of ECMO-associated pneumonia. Univariate and multivariate Cox analyses were used to identify risk factors of treatment failure among patients with VAP. In both cases, all variables associated (p \< 0.10) with the outcome in the univariate analysis were introduced into the multivariate model. Relative risks (RR) for Poisson model and hazard ratios (HR) for Cox model were calculated with their 95% confidence intervals (CI).

Significance was defined as p-values less than 0.05. Statistical analyses were performed using R 3.3.3 (<http://www.R-project.org>).

Results {#sec014}
=======

Population {#sec015}
----------

Between January 2013 and December 2014, 163 patients were assisted by VA-ECMO and retrospectively included in our database. Of these 163 patients, 11 died within the 48 first hours and were not included in the study. Demographic and clinical characteristics of the 152 patients with ECMO support \> 48 hours are described in [Table 1](#pone.0194976.t001){ref-type="table"}. VA-ECMO was implanted mainly for left ventricular failure (N = 66, 43.4%), for a period of 10.7 (8.6) days, with duration of mechanical ventilation of 14.4 (12.7) days and an ICU stay of 26.3 (24.8) days. Five patients were assisted with central cannulation (3,3%).

10.1371/journal.pone.0194976.t001

###### Baseline characteristics.

![](pone.0194976.t001){#pone.0194976.t001g}

  All patients (N = 152)                      Results N (%) or mean (± SD)
  ------------------------------------------- ------------------------------
  Age (years)                                 59 ± 15
  Male sex                                    112 (73.7%)
  BMI (Kg.m^-2^)                              25.1 ± 6.1
  SAPS 2                                      54.4 ± 22.3
  SOFA                                        11 ± 5
  Euroscore2                                  21.4 ± 15.8
  Creatinine clearance (mL.min^-1^)           77 ± 36
  LVEF (%)                                    30 ± 16.0
  Hypertension                                87 (57.2%)
  Tobacco                                     72 (47.7%)
  COPD                                        32 (21.0%)
  Diabetes                                    35 (23.0%)
  Liver cirrhosis                             11 (7.2%)
  Immunosuppression                           42 (27.6%)
  Reason for ECMO                             
  Left Ventricular Failure                    66 (43.4%)
  Right Ventricular Failure                   43 (28.3%)
  Biventricular Failure                       34 (22.4%)
  Cardiac Arrest                              9 (5.9%)
  ECMO implantation                           
  Pre cardiotomy                              46 (30.3%)
  Per cardiotomy                              71 (46.7%)
  Post cardiotomy                             37 (24.2%)
  Localization of implantation                
  Operating Room                              67 (44.4%)
  ICU                                         84 (55.6%)
  Prophylactic antibiotic at implantation     103 (69.1%)
  Duration of ECMO support (days)             10.7 ± 8.6
  Duration of Mechanical Ventilation (days)   14.4 ± 12.7
  Duration of ICU stay (days)                 26.3 ± 24.8
  Duration of hospital stay (days)            42.7 ± 43.8
  Infectious complications                    
  Bacteremia                                  53 (34.9%)
  Ventilator-Associated Pneumonia             85 (55.9%)
  Local infection of the cannulation site     37 (24.3%)
  Catheter-Related Infection                  11 (7.2%)
  Urinary Tract Infection                     5 (7.9%)
  Mediastinitis                               17 (11.2%)
  Hemorrhagic complications                   
  Local hemorrhage of the cannulation site    20 (13.2%)
  Surgical Site hemorrhage                    41 (27.0%)
  Digestive complications                     
  Gastrointestinal hemorrhage                 23 (15.1%)
  Mesenteric ischemia                         8 (5.3%)
  Neurologic complications                    
  Ischemic stroke                             21 (13.9%)
  Hemorrhagic stroke                          9 (5.9%)
  Limb ischemia                               18 (11.8%)
  Renal Replacement Therapy                   93 (61.2%)
  28-Day mortality                            48 (31.6%)
  ICU Mortality                               69 (45.4%)

BMI: Body Mass Index; ASA: American Society of Anesthesiologists; SAPS2: Simplified Acute Physiology Score 2; LVEF: Left Ventricular Ejection Fraction; COPD: chronic obstructive pulmonary disease. Data are No. (%) of patients or mean value (± standard deviation)

Description of ventilator-associated pneumonia under ECMO support {#sec016}
-----------------------------------------------------------------

VAP occurred in 85 (55.9%) patients, for a rate of 60.6 per 1000 ECMO days. Diagnosis of VAP was realized with a delay of 5 \[3;12\] days after ICU admission, 3 \[2;8\] days after ECMO implantation and 3 \[2--10\] days after endotracheal intubation. Patients' characteristics and diagnosis criteria are summarized in [S1](#pone.0194976.s001){ref-type="supplementary-material"} and [S2](#pone.0194976.s002){ref-type="supplementary-material"} Tables. *Pseudomonas aeruginosa* (n = 22, 18.2%) was the most frequent isolated pathogen (see [Table 2](#pone.0194976.t002){ref-type="table"}).

10.1371/journal.pone.0194976.t002

###### Pathogens isolated from respiratory samplings.

![](pone.0194976.t002){#pone.0194976.t002g}

  Pathogen                          No (%)
  --------------------------------- -----------
  **Bacteria**                      
  Gram-negative Pathogens           
  *Enterobacteriaceae*              
  *Escherichia coli*                10 (8.3)
  *Enterobacter cloacae*            11 (9.0)
  *Klebsiella pneumoniae*           8 (6.6)
  *Klebsiella oxytoca*              3 (2.5)
  *Hafnia alvei*                    2 (1.6)
  *Citrobacter koseri*              3 (2.5)
  *Citrobacter freundii*            1 (0.8)
  *Serratia marcescens*             5 (4.1)
  *Proteus mirabilis*               2 (1.6)
  *Neisseria sicca*                 2 (1.6)
  *Proteus vulgaris*                1 (0.8)
  *Other Gram-negative pathogens*   
  *Pseudomonas aeruginosa*          22 (18.2)
  *Stenotrophomonas maltophilia*    3 (2.5)
  Gram-positive Pathogens           
  *Staphylococcus aureus*           7 (5.8)
  *Oral streptococci*               1 (0.8)
  *Streptococcus dysgalactiae*      2 (1.6)
  *Enterococcus faecalis*           1 (0.8)
  Other                             
  *Haemophilus influenzae*          7 (5.9)
  Commensal oropharyngeal flora     23 (19.0)
  *Bacteroides fragilis*            1 (0.8)
  **Other pathogens**               
  *Candida albicans*                3 (2.5)
  *Candida glabrata*                1 (0.8)
  *Herpes simplex virus*            2 (1.6)

Occurrence of a VAP was associated with increased length of ECMO assistance duration (HR 1.47 \[1.05--2.05\], p = 0.025) and an increased mortality (HR 3.05 \[1.66;5.63\], p \< 0.001) as illustrated on "[Fig 1](#pone.0194976.g001){ref-type="fig"}", but not with the duration of mechanical ventilation (HR 0.86 \[0.60--1.23\], p = 0.406).

![Kaplan-Meier analysis of the probability of survival according to the presence of a VAP during ECMO support.\
The 28-day survival was significantly lower in the VAP group (red line) in comparison to the no VAP group (black line) (nominal p \< 0.001).](pone.0194976.g001){#pone.0194976.g001}

Risk factors of VAP under ECMO support {#sec017}
--------------------------------------

In univariate analysis, risk factors for VAP were: age \> 65 years old (RR \[CI95%\] 1.73 \[1.13;2.63\], p = 0.01), SOFA score at admission (1.09 \[1.02;1.17\], p = 0.01), history of hypertension (2.25 \[1.43;3.53\], p = 0.0004), active smoking (1.55 \[0.96;2.49\], p = 0.07) and COPD (2.15 \[1.30;3.55\], p = 0.003) whereas the female gender (0.44 \[0.24;0.81\], p = 0.008) was protective (see [Table 3](#pone.0194976.t003){ref-type="table"}). Due to too many missing data, SOFA score at admission was not included in the multivariate analysis, which found only the female gender as associated with a decrease in the incidence of VAP (0.52 \[0.30;0.91\], p = 0.02). Due to the small number of patients with central cannulation (N = 5) present in this subgroup and therefore the insufficient power, we did perform any statistical analysis.

10.1371/journal.pone.0194976.t003

###### Risk factors for VAP under ECMO.
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  Variable               No VAP N = 67   VAP N = 85     Univariate analysis   Multivariate analysis                        
  ---------------------- --------------- -------------- --------------------- ----------------------- -------------------- ------
  Age \> 65 years old    24 (35.8)       30 (35.3)      1.73 \[1.13;2.63\]    0.01                    1.22 \[0.76;1.96\]   0.41
  Sex (female)           24 (35.8)       16 (18.8)      0.44 \[0.24;0.81\]    0.008                   0.52 \[0.30;0.91\]   0.02
  Euroscore2             22.52 (16.5)    20.46 (15.2)   0.99 \[0.97;1.01\]    0.23                                         
  SAPS2                  48.07 (19.2)    60.34 (23.7)   1.01 \[1.00;1.03\]    0.08                                         
  SOFA                   9.28 (4.2)      11.75 (5.6)    1.09 \[1.02;1.17\]    0.01                                         
  Diabetes mellitus      13 (19.4)       22 (25.9)      1.64 \[0.91;2.97\]    0.1                                          
  Hypertension           37 (55.2)       50 (58.8)      2.25 \[1.43;3.53\]    0.0004                  1.57 \[0.93;2.67\]   0.09
  Active smoker          28 (42.42)      44 (51.8)      1.55 \[0.96;2.49\]    0.07                    1.02 \[0.59;1.76\]   0.94
  COPD                   13 (19.4)       19 (22.3)      2.15 \[1.30;3.55\]    0.003                   1.18 \[0.62;2.25\]   0.61
  Creatinine clearance   76.3 (35.0)     76.7 (37.4)    1.00 \[0.99;1.00\]    0.27                                         
  Immunosuppression      15 (22.4)       27 (31.8)      1.11 \[0.66;1.86\]    0.69                                         

SAPS2: Simplified Acute Physiology Score; SOFA: Sequential Organ Failure Assessment; COPD: chronic obstructive pulmonary disease; Data are No. (%) of patients or mean value ± standard deviation.

Treatment failure {#sec018}
-----------------

VAP recurrence was diagnosed in 32 patients (37.2%), with 10 persistences (11.8%), 8 relapses (9.4%), and 19 superinfections (22.3%). Gram-negative bacteria were identified in 86% of VAP recurrences, including 51% *Pseudomonas aeruginosa* and 35% Enterobacteriaceae. No clinical or biological parameters predicted the occurrence of recurrence ([S2 Fig](#pone.0194976.s004){ref-type="supplementary-material"}). Treatment failure was identified in 31.8% of patients (N = 27 patients). Among these patients, 92.3% (N = 24) were initially treated with appropriate antibiotics, versus 86.4% (N = 46) of the patients without treatment failure (P = 0.2765). In multivariate analysis, only renal replacement therapy at pneumonia diagnosis (HR 13.05 \[1.73; 98.56\], p = 0.013) and identification of *Pseudomonas aeruginosa* as the pathogen responsible for the first episode of pneumonia (HR 2.36 \[1.04; 5.35\], p = 0.04) were associated with treatment failure (see [Table 4](#pone.0194976.t004){ref-type="table"}).

10.1371/journal.pone.0194976.t004

###### Risk factors for VAP treatment failure in patients assisted with ECMO.
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  Variable                              No VAP N = 67   VAP N = 85      Univariate analysis     Multivariate analysis                          
  ------------------------------------- --------------- --------------- ----------------------- ----------------------- ---------------------- -------
  Age (years old)                       57.38 (14.92)   64.26 (11.4)    1.03 \[1;1.06\]         0.0510                  1.00 \[0.97;1.04\]     0.802
  Sex (female)                          13 (22.41%)     3 (11.11%)      0.48 \[0.14;1.59\]      0.2273                                         
  BMI (Kg.m^-2^)                        24.8 (4.41)     24.9 (5.8)      1.01 \[0.93;1.1\]       0.7432                                         
  SOFA score                            11.25 (5.47)    13.25 (5.99)    1.1 \[0.97;1.25\]       0.1324                                         
  Active smoker                         28 (48.28)      16 (59.26)      1.46 \[0.67;3.14\])     0.3386                                         
  COPD                                  12 (20.69)      7 (25.93)       1.34 \[0.57;3.18\]      0.5008                                         
  Liver cirrhosis                       7 (12.07)       3 (11.11)       0.9 \[0.27;2.99\]       0.86                                           
  Left ventricle unload                 29 (50.88)      13 (48.15)      0.83 \[0.39;1.77\]      0.6322                                         
  Duration of MV before VAP diagnosis   6.24 (6.64)     6.85 (7.19)     1.01 \[0.96;1.06\]      0.7334                                         
  Creatinine Clearance                  80.67 (37.75)   68.12 (35.98)   0.99 \[0.98;1\]         0.1287                  1.00 \[0.98;1.01\]     0.431
  RRT at VAP diagnosis                  32 (55.17)      26 (96.3)       18.31 \[2.47;135.55\]   0.0044                  13.05 \[1.73;98.56\]   0.013
  Immunosuppression                     19 (32.76)      8 (29.63)       0.89 \[0.39;2.02\]      0.7726                                         
  Bacteremia                            7 (12.07)       4 (14.81)       1.37 \[0.47;3.96\]      0.5639                                         
  MDR pathogen VAP                      6 (10.34)       5 (18.52)       1.53 \[0.58;4.03\]      0.3948                                         
  *P*. *aeruginosa* VAP                 8 (13.79)       12 (44.44)      3.02 \[1.41;6.49\]      0.0046                  2.36 \[1.04;5.35\]     0.04

COPD: chronic obstructive pulmonary disease; MV: mechanical ventilation; VAP: ventilator-associated pneumonia; RRT: Renal Replacement Therapy; MDR: multidrug resistant

Data are No. (%) of patients or mean value (± standard deviation).

Discussion {#sec019}
==========

In this large retrospective cohort study in VA-ECMO patients, VAP occurs in 56% of patients, early after VA-ECMO implantation, and increases significantly the 28-day mortality. Treatment failure was identified as a frequent event, associated with the documentation of *Pseudomonas aeruginosa* and the presence of renal replacement therapy at diagnosis. The previously published studies about infectious complications under ECMO support are either pediatric patients-focused \[[@pone.0194976.ref014]\], from large international registries \[[@pone.0194976.ref004]\], or interested in all types of infections, and did not address this specific issue, whereas VAP remains the main infection in intensive care \[[@pone.0194976.ref015]\] as in ECMO patients \[[@pone.0194976.ref004]--[@pone.0194976.ref006]\].

Incidence of infections under ECMO and particularly VAP varies greatly depending the studies, ranging from 14.8 to 75.5 infectious episodes per 1000 days of ECMO \[[@pone.0194976.ref003]--[@pone.0194976.ref006]\]. With a rate of 60.6 per 1000 ECMO days, our results are in the high range of previously published studies, probably linked to the severity of our patients (SAPS 2 score at admission of 54.4 (22.3)) and to the extensive review of hospitalization reports, including daily observation, biological and microbiological data.

Moreover, since cardiopulmonary bypass (CBP) is know to induce an immunosuppression, decreasing monocyte response to pathogens \[[@pone.0194976.ref007]--[@pone.0194976.ref009]\] and significant reduction of HLA-DR and TLR4 expression on alveolar macrophages \[[@pone.0194976.ref016]\], ECMO could induce the same alterations that CBP and thus predispose patients to infectious complications, in particular pneumonia. However, to the best of our knowledge, there is no pre-clinical data to support this hypothesis so far. Finally, it is interesting to note that the main microorganisms documented in our cohort were Enterobacteriaceae (39.4%) and *Pseudomonas aeruginosa* (18.2%), even though pneumonia was an early event during assistance. This proportion is similar to that found in the post cardiac surgery context \[[@pone.0194976.ref017]\], and could be linked with a bacterial translocation in this context of circulatory failure.

In our cohort, Renal Replacement Therapy (RRT) and documentation of *Pseudomonas aeruginosa* were associated with treatment failure. The increase of volume of distribution as much as the antibiotic drug sequestration in the circuit secondary to ECMO could accentuate the pharmacokinetic alterations seen in critically ill patients, leading to poor achievement of target concentrations of antibiotics, especially hydrophilic antibiotics used against *P*. *aeruginosa* (e.g., aminoglycosides, beta-lactams) \[[@pone.0194976.ref018]\]. Moreover, RRT is known to add a significant variability in antibiotic concentrations \[[@pone.0194976.ref019],[@pone.0194976.ref020]\]. Hence, it was shown that the combination of ECMO and RRT could alter meropenem pharmacokinetic, especially for *P*. *aeruginosa* \[[@pone.0194976.ref011]\].

Our study suffers from several limitations. The diagnosis of VAP is challenging for clinicians \[[@pone.0194976.ref021]\], and even more in patients assisted with ECMO, since the parameters usually used for VAP diagnosis are not interpretable in this setting \[[@pone.0194976.ref022],[@pone.0194976.ref023]\]. Hence, to our knowledge, the diagnosis criteria of pneumonia are not specified in any of the above studies about infections under ECMO support. In our study, VAP was defined *post hoc* by 2 independent investigators (AB, CB) on the basis of clinical and radiological data, and systematically confirmed with a positive quantitative culture of a respiratory sample at significant threshold. Although all patients assisted with VA-ECMO between January 2013 and December 2014 were included and analyzed, the retrospective design of the study as well as the relatively low sample size of the cohort limits the strength of our findings. In addition, even though SOFA score was significant in the univariate analysis of risk factors for pneumonia, the large number of missing data did not allow us to integrate it into the multivariate analysis. Finally, the monocentric design of the study limits its external reproducibility, even if a large cohort obtained on a short period and in a single center guarantees homogeneity of management.

Conclusion {#sec020}
==========

VAP is a frequent and severe complication in patients treated with VA-ECMO, and is associated with an increased morbidity and mortality. RRT during antibiotic therapy and infection by *Pseudomonas aeruginosa* appear as strong risks factors of treatment failure. The best antibiotic management in patients with RRT and with ECMO remains to be determined.
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